Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Globe Newswire•23/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.